Ready-to-use AAV2 particles produced from pAAV-CAG-eYFP (#104055). In addition to the viral particles, you will also receive purified pAAV-CAG-eYFP plasmid DNA. CAG-driven eYFP expression control. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV2 particles produced from pAAV-mDlx-NLS-mRuby2 (#99130). In addition to the viral particles, you will also receive purified pAAV-mDlx-NLS-mRuby2 plasmid DNA. mDlx-driven NLS-mRuby2 expression. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from pAAV-mDlx-NLS-mRuby2 (#99130). In addition to the viral particles, you will also receive purified pAAV-mDlx-NLS-mRuby2 plasmid DNA. mDlx-driven NLS-mRuby2 expression. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV9 particles produced from pAAV-mDlx-NLS-mRuby2 (#99130). In addition to the viral particles, you will also receive purified pAAV-mDlx-NLS-mRuby2 plasmid DNA. mDlx-driven NLS-mRuby2 expression. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from pAAV-CAG-fDIO-mNeonGreen (#99133). In addition to the viral particles, you will also receive purified pAAV-CAG-fDIO-mNeonGreen plasmid DNA. CAG-driven, Flp-dependent mNeonGreen expression. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from TRE-DIO-eYFP (#117383). In addition to the viral particles, you will also receive purified TRE-DIO-eYFP plasmid DNA. Tet-inducible, Cre-dependent eYFP expression. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from pAAV-ihSyn1-tTA (#99120). In addition to the viral particles, you will also receive purified pAAV-ihSyn1-tTA plasmid DNA. Expression of the tet-off transactivator from an inducible synapsin promoter. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from pAAV-ihSyn1-DIO-tTA (#99121). In addition to the viral particles, you will also receive purified pAAV-ihSyn1-DIO-tTA plasmid DNA. Cre-dependent expression of the tet-off transactivator from an inducible synapsin promoter. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV8 particles produced from pAAV-mDlx-NLS-mRuby2 (#99130). In addition to the viral particles, you will also receive purified pAAV-mDlx-NLS-mRuby2 plasmid DNA. mDlx-driven NLS-mRuby2 expression. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV PHP.eB particles produced from hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV PHP.eB particles produced from CAG-NLS-GFP (#104061). In addition to the viral particles, you will also receive purified CAG-NLS-GFP plasmid DNA. CAG-driven NLS-GFP expression. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV PHP.eB particles produced from pAAV-CAG-eYFP (#104055). In addition to the viral particles, you will also receive purified pAAV-CAG-eYFP plasmid DNA. CAG-driven eYFP expression control. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV Retrograde particles produced from hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV Retrograde particles produced from pAAV-CAG-eYFP (#104055). In addition to the viral particles, you will also receive purified pAAV-CAG-eYFP plasmid DNA. CAG-driven eYFP expression control. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV PHP.eB particles produced from pAAV-mDlx-NLS-mRuby2 (#99130). In addition to the viral particles, you will also receive purified pAAV-mDlx-NLS-mRuby2 plasmid DNA. mDlx-driven NLS-mRuby2 expression. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV PHP.V1 particles produced from pAAV-CAG-DIO-EYFP (#104052). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-EYFP plasmid DNA. CAG-driven, Cre-dependent expression of EYFP. These AAV were produced with the PHP.V1 serotype, which permits efficient transduction of brain vascular cells. These AAV preparations are suitable purity for injection into animals.